bromantane vs Noopept (omberacetam; GVS-111)
updated
bromantane (tier B) vs Noopept (omberacetam; GVS-111) (tier B): what each is, why each got its grade, half-life and source counts side by side.
bromantane · tier B
a Russian antiasthenic CNS drug with older human studies in illness-related fatigue, incomplete modern replication, no traceable primary human half-life source, and in-competition WADA prohibition.
tier rationale
B-tier reflects a real approved-abroad drug history and multiple human studies, including a 728-patient multicenter asthenia report. It stays below A because the evidence is older, geographically concentrated, incompletely accessible, focused on diagnosed asthenia rather than healthy performance, and missing the kind of modern PK and long-term safety package expected for broad claims.
Noopept (omberacetam; GVS-111) · tier B
omberacetam, a small-molecule cognitive drug sold as a registered 10 mg oral tablet in Russia. the cited human signal comes from one small patient comparison, not a healthy-user trial.
tier rationale
B-tier reflects a current foreign registration, one small positive active-comparator patient study, and direct but sparsely reported human pharmacokinetics. It stays below A because the clinical study had no placebo or healthy-user group, long-term healthy-user safety is absent, and US supplement identity is a separate unresolved problem.
at a glance
| bromantane | Noopept (omberacetam; GVS-111) | |
|---|---|---|
| tier | B | B |
| category | nootropic / longevity | nootropic / longevity |
| sources | 7 | 12 |
| claims evaluated | 4 | 3 |
| half-life | not structured; the repeated 11.21-hour human claim was not traced to an accessible primary PK source | 22.05 plus or minus 14.37 minutes in a sparsely reported human conference abstract |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.